skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Characteristics of doripenem: a new broad-spectrum antibiotic

Review

(4129) Views  (1290) Full article downloads

Authors: Francisco Alvarez-Lerma, Santiago Grau, Olivia Ferrández

Published Date May 2009 Volume 2009:3 Pages 173 - 190
DOI: http://dx.doi.org/10.2147/DDDT.S3083

Francisco Alvarez-Lerma1, Santiago Grau2, Olivia Ferrández2

1Intensive Care Unit, 2Pharmacy Department, Hospital Del Mar, Barcelona, Spain

Abstract: Doripenem (S-4661) is a new parenteral antibiotic from the carbapenem class; similarly to imipenem and meropenem, it has a broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria. It is active against multiresistant Gram-negative bacilli such as extended-spectrum beta-lactamase-producing (ESBL) Gram-negative Enterobacteriaceae and nonfermentative Gram-negative bacilli including some strains of Pseudomonas aeruginosa that are resistant to other carbapenems. Doripenem’s chemical structure is similar to that of meropenem (substitution of one sulfamoxil-aminomethyl chain for the dimethyl-carboxyl chain), and has one 1-beta-methyl chain which provides resistance to dehydropeptidase-I enzyme. The clinical trials conducted so far have focused on the treatment of severe infections such as complicated intra-abdominal infections, complicated urinary tract infections and pyelonephritis, nosocomial pneumonia, and ventilator-associated pneumonia. Given its activity profile and the results from the clinical trials, this antibiotic may be used for empirical treatment of multibacterial infections produced by potentially multiresistant Gram-negative bacilli. In 2007, the US Food and Drug Administration approved the use of doripenem for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. The European Medicines Agency has approved the use of doripenem for the same indications in addition to nosocomial pneumonia regardless of whether it is ventilator-associated or not.

Keywords: doripenem, antimicrobial activity, clinical efficacy, pharmacokinetics, tolerability








Readers of this article also read:

Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex
Indiplon in the management of insomnia
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
Emerging treatments in the management of schizophrenia – focus on sertindole
Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis
Current and emerging drugs for the treatment of inflammatory bowel disease
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University